Actively Recruiting
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Led by Janssen Research & Development, LLC · Updated on 2026-05-08
300
Participants Needed
15
Research Sites
264 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).
CONDITIONS
Official Title
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male participants aged 18 years or older
- Diagnosis of metastatic castration-resistant prostate cancer (mCRPC) with confirmed adenocarcinoma as per PCWG3 criteria or metastatic hormone-sensitive prostate cancer (mHSPC) with specific PSA levels
- Measurable or evaluable disease (except for Part 2H)
- Prior treatment with at least one androgen receptor pathway inhibitor (ARPI) or chemotherapy as specified for each study part
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ function as determined by study assessments
You will not qualify if you...
- Active autoimmune disease within 12 months requiring systemic immunosuppressive medication
- Ongoing toxicity from prior anticancer therapy greater than Grade 1 (except certain conditions like alopecia and mild neuropathy)
- History of solid organ or bone marrow transplant
- Known allergies or intolerance to study drugs or their components
- Significant infections or serious medical conditions affecting lung, heart, or other organs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
Florida Cancer Specialists
Sarasota, Florida, United States, 34232
Actively Recruiting
2
Start Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
3
Washington University School Of Medicine
St Louis, Missouri, United States, 63110
Actively Recruiting
4
Perlmutter Cancer Center at NYU Langone Brooklyn
Brooklyn, New York, United States, 11223
Actively Recruiting
5
Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island
Mineola, New York, United States, 11501
Actively Recruiting
6
NYU Langone Health
New York, New York, United States, 10016
Actively Recruiting
7
Sidney Kimmel Cancer Center - Jefferson Health
Philadelphia, Pennsylvania, United States, 19107
Actively Recruiting
8
Icon Cancer Centre Kurralta Park
Kurralta Park, Australia, 5037
Actively Recruiting
9
Macquarie University
Macquarie University, Australia, 2109
Actively Recruiting
10
Peter MacCallum Cancer Centre
Melbourne, Australia, 3000
Actively Recruiting
11
Princess Alexandra Hospital
Woolloongabba, Australia, 4102
Actively Recruiting
12
Hosp Univ Vall D Hebron
Barcelona, Spain, 8035
Actively Recruiting
13
Hosp Univ Fund Jimenez Diaz
Madrid, Spain, 28040
Actively Recruiting
14
Hosp. Univ. 12 de Octubre
Madrid, Spain, 28041
Actively Recruiting
15
Hosp Univ Hm Sanchinarro
Madrid, Spain, 28050
Actively Recruiting
Research Team
S
Study Contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here